AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI) AKI […]

AM-Pharma haalt €116 miljoen ($133 miljoen) financiering op voor fase III registratie-studie met kandidaat-medicijn tegen acuut nierfalen (AKI)

Grootste biotech VC financieringsronde ooit in Nederland, geleid door nieuwe investeerders LSP en Andera Partners met deelname van bestaande investeerders Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures en Gilde Healthcare Opbrengst bestemd voor internationale Fase III-registratie-studie met ‘recombinant humaan Alkalische Fosfatase’ (recAP) bij 1.400 patiënten met sepsis (bloedvergiftiging) -geassocieerd acuut nierfalen […]

AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the […]

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Option may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase Bunnik, The Netherlands, and New York, NY – 11 May 2015 – AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP ) for inflammatory diseases, and Pfizer Inc. (NYSE: PFE) announced […]

AM-Pharma closes €12.2m financing round

New capital to complete Phase II development of recAP in Acute Kidney Injury Bunnik, The Netherlands, 11 September 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors AbbVie, BB […]

AM-Pharma Raises €29.2m in Series D Financing

Bunnik, The Netherlands, 13 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for  treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing. The series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners […]

AM-Pharma announces loan of up to €5 million from Dutch Government

Dutch Government supports AM-Pharma in development of first drug against Acute Kidney Injury Bunnik, The Netherlands, March 19, 2009. AM-Pharma B.V., the biopharmaceutical company developing endogenous proteins to combat disease, today announced it is receiving a loan of up to €5 million from SenterNovem, an agency of the Dutch Ministry of Economic affairs. The loan […]

AM-Pharma announces €7 million First Close of series C financing round

Existing investors support AM-Pharma and set the terms for Second Close Bunnik, The Netherlands, 28 May 2008. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins and peptides to combat disease, today announced the signing of a €7 million financing agreement with Forbion Capital Partners and Inventages Venture Capital. The announced investment is a First […]

AM-Pharma announces €2.5 million financing

Bunnik, The Netherlands, 3 August 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the signing of a €2.5 million financing agreement with its two main investors, Forbion Capital Partners and Inventages Venture Capital. The investment is a prelude to a Series C financing round, for which AM-Pharma is […]